Antitumor Effect of Nivolumab on Subsequent Chemotherapy for Platinum‐Resistant Ovarian Cancer

Platinum‐resistant recurrent ovarian cancer is generally refractory to chemotherapy. Programmed cell death‐1 (PD‐1) signaling is a new target for antitumor therapy. The anti‐PD‐1 antibody nivolumab had a 10% durable complete response rate in our phase II clinical trial. However, how nivolumab affect...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Inayama, Yoshihide, Hamanishi, Junzo, Matsumura, Noriomi, Murakami, Ryusuke, Abiko, Kaoru, Yamaguchi, Ken, Baba, Tsukasa, Horie, Katsuyuki, Konishi, Ikuo, Mandai, Masaki
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2018
Assuntos:
Brief Communications
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6291322/
https://ncbi.nlm.nih.gov/pubmed/30158286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0167
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados